Conformis Enters License Agreement with Paragon 28

By Julie A. Vetalice

Conformis Enters License Agreement with Paragon 28

Conformis entered into an agreement with Paragon 28, granting the company a non-exclusive license under a subset of Conformis’ U.S. patents for the use of patient-specific instruments with off-the-shelf implants in Paragon 28’s APEX 3D™ Total Ankle.

The APEX system gained FDA 510(k) clearance in 2020.

“We are pleased to reach this agreement with Paragon 28, enabling it to incorporate our patient-specific instrument technology in its anticipated total ankle replacement offering,” said Mark Augusti, President and Chief Executive Officer. “We believe that this latest license agreement further demonstrates the broad applicability and clinical appeal of Conformis’ technology.”

Product Labels: Ankle Replacement